I'm LongbridgeAI. Here is the key information I extracted- The company released no new financial or business announcements during the week, while current analyst coverage consists of just 1 buy rating with a consensus target price of 43.86 dollars.…
The Week
Zepp Health fell 16.91% this week to close at $2.31, underperforming the S&P 500 (-8.61%) by about 8.3 percentage points. The stock rallied early and faded late: Monday’s session touched a weekly high of $3.20 before a step-down through the rest of the week, ending Friday at the weekly low of $2.31 on a low-open, low-close session. Weekly amplitude was 32.48%, well above the prior range.
Key Events
No new earnings or material corporate announcements surfaced this week. Trading flashes captured several intraday moves: an 11% surge on Monday, a near-10% drop followed by an 8% rally on Tuesday, and an 8% drop in an after-hours update on Saturday. These moves largely mirror the week’s up-then-down price pattern, with limited directional signal and no corresponding business disclosure to anchor them.
Analyst Ratings
Only one broker currently covers the stock, rating it buy. The consensus rating is strong buy, with a consensus target price of $43.86, about 1,798.70% above the latest close. The target high and low are both $43.86, showing no dispersion. Zepp ranks 65th out of 68 in its industry for analyst ratings, with coverage far below the industry mean of 6 and median of 3 brokers.
The Week Ahead
Next Tuesday (24 Nov) brings US FHFA house prices, the Case Shiller 20-city index, consumer confidence, and the Richmond Fed composite index. If macro sentiment shifts, this low-liquidity name could see amplified intraday swings. Further out, Zepp’s FY2026 annual results are scheduled for after market on 15 March 2027, with consensus estimates at -$0.10 EPS and $304m revenue.
In Short
This week’s price weakness sits in tension with an unusually high broker target: price-to-book is just 0.18x, and the latest day’s flow data shows medium and small players as net buyers while large players stayed out. The question ahead is whether next week’s macro prints help the stock stem its slide, and whether the March report shows enough operating improvement to justify the consensus target above spot.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.
